Sales in Q4 from what I found on I/o, eve had more and longer top tens in the third quarter than in Q4. So what will Q4 revenues be? My guess is, that unless there have been many more unreported sales to Germany, Q4 revenues will be flat or less than Q3.
Because of Eve's silence, I can only speculate what expenses are. What status are the payables in?
Finance costs? Rewritten or in default?
Were there any new crops grown?
Inventory?
New management structure? Any changes?
Operating expenses?
What about these two......""On August 6, 2020, the Company announced a licensing agreement with Colio Estate Wines (“Colio”) for the development of a premium cannabis-infused beverage for distribution by Eve & Co and licensing of Colio’s Girls’ Night Out brand. The Company expects to introduce its co-branded infused beverage products to the adult-use cannabis market later in 2021.
On December 15, 2020, the Company announced that it had entered into a licensing agreement with Wellness Results Inc. (“Dr. Kerklaan Therapeutics”) to establish the exclusive right and license to manufacture, import and export, warehouse, package, advertise, market, distribute and sell the following products in Canada under the Dr. Kerklaan Therapeutics brand, under the Eve & Co brand, or as co-branded products ............... The Company anticipates manufacturing and distributing cannabis-infused topicals to the Canadian market in the second half of 2021.